Monte Carlo Capital is a venture capital firm that invests in founders in Europe, the UK, and the US. The company provides capital over multiple stages, starting at seed, and brings in an ecosystem of people to support founders.

Monte Carlo Capital

Alectio provides a DataPrepOps platform designed for data-centric AI workflows, aiming to improve model training efficiency and reduce the amount of data required.

Alectio

Starburst Data provides a data lakehouse platform built with Trino, enabling secure access, analysis, and sharing of data for analytics and AI across hybrid, on-premises, and multi-cloud environments. The platform is self-described as scalable and reliable for handling complex queries.

Starburst Data

Monte Carlo Capital was founded in 2009 by former investment banker Ian Sosso, winner of the 2019 “Best European Early Stage Investor” award from EBAN, the Brussels-based European trade association for business angels representing the 30,000 European angel community with a presence in 50 countries. 

Monte Carlo Capital combines the best features of business angels and venture capital. We invest via fund and via SPVs. We have been the Lead in many of our investments and are increasing our Co-Investments with some of the world’s leading VCs. Typical investments start at pre-seed/seed and we regularly follow on to Series A & Series B rounds.  

Monte Carlo Capital invests across sectors, including Saas, Fintech, DeepTech and Health Care, in the US, Europe and the UK.

We are delighted to announce our 8th investment from the fund in Barcelona based SOM Biotech, a Biotech company focusing on orphan drugs using an algorithm to identify candidates for drug repurposing
 
 
Here is what SOM Biotech does in a nutshell: 
 
Drug repurposing is the process of identifying potential new therapeutic uses (or 'indications') for older medicines through new research and evidence. Two of the most well know drugs are Viagra (does not need an introduction) and Minoxidil (against hair loss). It is estimated that over 25% of drugs on the market are repurposed.

One key benefit of drug repurposing is that data is usually available for the old drug, both for safety profile (albeit for specific dosing) and efficacy (albeit for a different indication).

Because there is significant data available, taking a known drug to the market is typically faster, cheaper and less risky than developing a new drug.
An orphan disease is a disease that has not been adopted by the pharmaceutical industry because it provides little financial incentive for the private sector to market new medications to treat or prevent it. Typically, each orphan disease affects fewer than 200,000 people. These orphan diseases represent a growing market estimated at $217B. 

A rare disease is a disease that affects a small percentage of the population. In some parts of the world, the term orphan disease describes a rare disease whose rarity results in little or no funding or research for treatments, without financial incentives from governments or other agencies. Orphan drugs are medications targeting orphan diseases.

No single number has been agreed upon for which a disease is considered rare. Global Genes has estimated that currently approximately 10,000 rare diseases exist globally, with 80% of these having identified genetic origins.
Orphan drugs command a higher profit margin than other drugs, owing to shorter clinical development time, incentives related to research and development, reduced marketing costs and premium pricing. Orphan drug designation also allows the manufacturer for a longer period of exclusivity than a regular drug.

SOM Biotech has been using an artificial intelligence algorithm to more accurately identify candidates for drug repurposing, has 1 candidate (for Huntington’s disease) in phase 2b, and is looking to bring one new molecule to clinical phase 2 yearly.
 
So how does SOM Biotech solve that problem: 
 
SOMAIPRO is a clinically validated AI engine that screens through 2.5 million iterations of molecular profiles of compounds to identify those most aligned with a reference compound from their own library. 
 
Follow their LinkedIn: https://lnkd.in/dfyVhWBH 
Check out their website: https://sombiotech.com/ 

Please remember to sign up for our newsletter: https://lnkd.in/e3zCYN_Z

#VC #emergingmanagers #familyoffice #biotech #angelinvesting #venturecapital #AI #startup #VentureCapital

We are delighted to announce our seventh investment from the fund in the Series A of LeaseTeq.
LeaseTeq is a Swiss-based technology company that aims to become the leading provider of technology to an old, inefficient and massive industry: auto leasing.
The ex-Porsche founders have built a digital platform that enables all key stakeholders (end customers, clients such as car manufacturers or dealerships, banks) to have a significantly more efficient experience than what they can currently find.
End users can get approval in a matter of minutes, dealers and OEMs provide a better experience to their customers and themselves, and banks are offered a platform allowing them to significantly improve the efficiency of their own leasing business, deal flow, and reduced servicing costs, thereby increasing the profitability of the business. Everyone wins.
The business started by operating a full fledged leasing business in Switzerland, demonstrating its significant value added, and has build a SaaS model, sold to the various stakeholders in the leasing industry including banks, classic leasing providers, dealerships and OEM leasing providers.
LeaseTeq is experiencing significant traction and growing in the DACH region. 

We are joined by other well-known investors such as Vi Partners (lead) and Anker Capital AG and we are excited for the journey ahead.
Check out their LinkedIn news release here:
https://lnkd.in/d5_TZdHM 
Follow their LinkedIn: https://lnkd.in/dKpGUex4
Check out their website: https://leaseteq.com/
Please remember to sign up for our newsletter, we send out regular news on Monte Carlo Capital, the latest trends in VC and upcoming webinars.
https://lnkd.in/e3zCYN_Z
#venturecapital #VC #emergingmanagers #angelinvesting #thefamilyofficeclub #familyoffice #leasing

Exciting news! AssetWatch®, formerly Nikola Labs, has just closed a $38M Series B funding round led by Wellington Management! 

As an early investor, having led four successive financings, I'm thrilled to see the company's amazing growth. 

You can read the full news release here: https://lnkd.in/dBEz_86f

Here is a nutshell of what AssetWatch does:
 
Unplanned downtime is a trillion-dollar annual problem for manufacturers, presenting a significant market opportunity for AssetWatch. Manufacturers in the United States alone lose 5% to 20% of productivity every year due to unplanned downtime, with equipment breakdowns (e.g., bearing, motor, and pump failure) being the leading cause. This can represent tens to hundreds of millions of dollars in lost income and is a key aspect of bottom-line profit.
 
Currently, the most common solution for maintenance is the “run to failure” or the “break/fix” model, where the machine or equipment breaks down unexpectedly. A team of technicians and mechanics is then sent out to investigate and hopefully repair the fault. This represents around 60% of machine monitoring maintenance today.
 
The other main solution is “routine/periodic maintenance,” where the machine undergoes inspection on a scheduled basis to check if all is in order. The problem with this is that often the machines are in good working order and don’t require maintenance, wasting time and money for both the technicians and the company, or the inspections are not frequent enough, resulting in machines breaking down between routine maintenance. Routine maintenance can also miss areas of potential failure, representing around 30% of machine monitoring maintenance.
 
This is where AssetWatch comes in. The company installs wireless sensors, commercially called Vero, on machines quickly and easily. The vibration and temperature sensors send data multiple times per day to the customer dashboard, providing early insight into bearing, motor, gearbox, and pump failure to give advance notice of potential issues. Today, more than 90% of installed manufacturing equipment lacks sensors that can predict those failures. The company aims to change that and help its customers avoid both unplanned downtime and costly breakdowns. 

Please remember to sign up for our newsletter: https://lnkd.in/e3zCYN_Z

#startup #venturecapital #VC #EBAN#emergingmanagers #angelinvesting #thefamilyofficeclub #tech #Monaco

I am excited to announce the ninth investment made from the fund in US-based Atreon Orthopedics, a MedTech company that is leveraging innovative nanofiber technology to change the orthopedic soft tissue market with its innovative electrospun and bioresorbable synthetic scaffolds. 

I was the lead investor in 3 of the early stages of ParaGen Technologies, Atreon's holding company when Atreon was a pre-seed company going through animal studies. Atreon has since received FDA clearance and has experienced strong revenue growth. We are investing in Series A of Atreon to further support its sales strategy in a sector that has seen high-value strategic acquisitions.

The problem addressed by Atreon:
 
Sports medicine injuries impact people of all ages and activity levels. For instance, rotator cuffs are one of the most common ones, impacting over 20% of the US general population. Despite advancements in surgical techniques, fixation methods, and instrumentation, the rotator cuff retear rate remains as high as +30% for most people with certain demographics facing a recurrence rate for new tears up to 60% of the time. Surgeons seek solutions that address the biological healing environment and improve repair quality.
 
Atreon Orthopedics® has developed a bioresorbable synthetic scaffold that is used in orthopedics for the management and repair of tendons to improve healing and decrease re-tear rate. The initial product is a graft utilized in rotator cuff repairs where it is placed on the bone and under the tendon, assisting the healing process by providing a scaffolding on which human cells can grow.
 
We are very excited to keep supporting Atreon Orthopedics® in its journey to redefining tissue engineering in the orthopedics field.

Please remember to sign up for our newsletter: https://lnkd.in/e3zCYN_Z 

#startup #venturecapital #VC #EBAN #emergingmanagers #angelinvesting #thefamilyofficeclub #medtech #Monaco

!! News: we are nominated for the best new VC fund award !!

The team at Monte Carlo Capital and I are thrilled to announce that we have been nominated for the best new VC fund of the year. The award winner will be announced at the leading European VC conference in Berlin on June 4th. We would be grateful if you could support us with this award by voting for us:

https://lnkd.in/dHpNAVjC

Meanwhile, we are finalizing our 9th (marketplace) and 10th investment (medical diagnostic). We will launch 2 co-invest SPVs with those investments - bringing the total of co-invest SPVs to 7, alongside the 10 investments from the fund.

Our first fund (targeted at EUR15M) is currently a little over 2/3 committed, with a hard close coming up in August 2024.

🇺🇸Immersive Fox🎬: Generative AI startup Immersive-Fox enables users, using a simple phone, to create their avatar, with their voice or a "borrowed voice", in 50+ languages, which can be used to add a video to marketing email campaigns, etc.

🇺🇸Klay🎶: NY-based Klay has brought together a group of industry veterans to build the leading AI Large Music Model, based on a tech initially stemming out of the MIT Media Lab.

🇺🇸Rollstack📈: San Francisco-based and fresh out of Y Combinator, Rollstack offers a seamless solution for enhancing slide and document management within teams' workflows for Google Slides and PowerPoint by using real-time data. With a simple 1-click update feature, keeping slides up to date becomes effortless.

🇺🇸AssetWatch®🛠️: AssetWatch is a portfolio company that we first invested in back in 2017 pre-revenue, and have led 4 successive financing rounds. With over 200 industrial groups as clients, the company is now positioning itself as the market leader in preventive maintenance.

🇺🇸Auriga Space🚀: Auriga, fresh out of the Seraphim Space accelerator, is developing a highly disruptive electromagnetic satellite launcher that offers significant advantages in launch cost, reliability, and frequency compared to conventional rocket launchers.

🇨🇭Hive-Zox🖲️: Hive Zox has created real-time data intelligence using a proprietary IoT monitoring device that allows the client to monitor 9 critical data points on a live basis. If something starts to go wrong with a shipment, the customer receives an immediate alert and actionable intelligent data.

🇨🇭LeaseTeq🔬: LeaseTeq is the first digital car leasing company, providing a significantly enhanced experience to all the stakeholders in an industry ripe for disruption.

🇪🇸SOM Biotech🔬: SOM Biotech leverages AI to find new applications for existing drugs. SOM focuses on orphan diseases and has a drug for Huntington's disease in a phase 2B trial. 

#startup #venturecapital #VC #EBAN #emergingmanagers #angelinvesting #familyoffice #thefamilyofficeclub #tech #privateequity #innovation #entrepreneurs #founders #entrepreneurship #Monaco #EUVC

Rollstack has build a category defining product. The data presentation paradox has long been recognized by data and business operators: platforms intended for data sharing (dashboards) are not where data is actually shared (slide decks and documents). Using AI, Rollstack bridges this gap, creating a new category in the space: Report Generation!

Metric
Company Name	Monte Carlo Capital	Alectio	Starburst Data
Symbol
MSH ID	COM:MONTECARLOCAP	COM:ALECTIO	COM:STARBURSTDATA
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Technology	Technology
Industry	Venture Capital	Software & IT Services	Software & IT Services
Country	MC	US	US
Stage
Employee Count	7	11
Website	montecarlocap.com	alectio.com	starburstdata.com
LinkedIn	monte-carlo-capital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		78
Web Traffic Growth		-0.48
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

MONT

COM:MONTECARLOCAP

Monte Carlo Capital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue